Navigating key news stories in pharma

Featured Stories

Featured
Balancing Innovation with Integrity in Pharma Packaging
Strategy
Balancing Innovation with Integrity in Pharma Packaging
Strategy

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

Read More →
Strategy
News
Intercept Withdraws Liver Disease Drug from U.S. Market
Regulatory
Intercept Withdraws Liver Disease Drug from U.S. Market
Regulatory

The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

Regulatory
Novo Unveils Transformation Plans to Better Compete in the Obesity Market
Strategy
Novo Unveils Transformation Plans to Better Compete in the Obesity Market
Strategy

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

Strategy
Argo Expands Collaboration with Novartis with siRNA Deal
Dealmaking
Argo Expands Collaboration with Novartis with siRNA Deal
Dealmaking

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

Dealmaking

Dealmaking

Featured
Argo Expands Collaboration with Novartis with siRNA Deal
Argo Expands Collaboration with Novartis with siRNA Deal

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

BioDuro, Atombeat Join Forces to Speed Up Peptide Drug Discovery
BioDuro, Atombeat Join Forces to Speed Up Peptide Drug Discovery

This partnership will leverage BioDuro’s expertise and Atombeat’s in silico modeling know-how to launch an AI-powered platform that allows for accelerated development of next-generation peptides.

MetaVia, Syntekabio Partner Up to Expand Therapeutic Potential of Oral GPR119 Agonist
MetaVia, Syntekabio Partner Up to Expand Therapeutic Potential of Oral GPR119 Agonist

The companies will work together, leveraging Syntekabio’s AI prediction platform for virtual screening to uncover new, high-potential indications for MetaVia’s DA-1241 oral therapy.

GSK, Hengrui Pharma Partner on Development of Up to 12 Innovative Medicines
GSK, Hengrui Pharma Partner on Development of Up to 12 Innovative Medicines

The strategic collaboration will also provide GSK with an exclusive worldwide license for Hengrui’s potential best-in-class PDE3/4 inhibitor, which is in clinical development as an add-on maintenance treatment for COPD.

Future Biopharma

Featured
Committing to a Sustainable Future in Biomanufacturing
Committing to a Sustainable Future in Biomanufacturing

With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

Making the Right Capacity Decisions at the Biomanufacturing Crossroads
Making the Right Capacity Decisions at the Biomanufacturing Crossroads

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

Approaching a Significant Transformation
Approaching a Significant Transformation

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Investing in Innovation to Capture Next-Gen Therapy Potential
Investing in Innovation to Capture Next-Gen Therapy Potential

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.
Bend Bioscience

R&D

Featured
Circio Demonstrates Increased AAV Potentcy with Circular RNA Technology
Circio Demonstrates Increased AAV Potentcy with Circular RNA Technology

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

CPTx and NanoCell Win European Funding for QUIET-CAR Project
CPTx and NanoCell Win European Funding for QUIET-CAR Project

The grant money will be used by the biotechs to develop innovative targeted lipid nanoparticles that contain novel immune-silent DNA constructs for in vivo CAR T therapy.

Preclinical Data Demonstrates Therapeutic Efficacy of Enveric’s Lead Candidate
Preclinical Data Demonstrates Therapeutic Efficacy of Enveric’s Lead Candidate

The company’s research in a well-established rodent model has shown that EB-003 has potential as an effective treatment for post-traumatic stress disorder, representing an opportunity in an underserved market.

Nanoform Receives Funding to Advance Clinical Development of Nanoapalutamide
Nanoform Receives Funding to Advance Clinical Development of Nanoapalutamide

Business Finland is providing Nanoform with a EUR 5 million R&D loan to be used to accelerate the clinical development of the nanoformulated version of apalutamide through to the pivotal bioequivalence study.

Expansion

Featured
Enzene Announces Official Inauguration of New U.S. Biomanufacturing Facility
Enzene Announces Official Inauguration of New U.S. Biomanufacturing Facility

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

Delpharm Set to Transform Boucherville Facility After Securing Government Funding
Delpharm Set to Transform Boucherville Facility After Securing Government Funding

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

Cohance Lifesciences Invests Heavily in Capabilities in India and U.S.
Cohance Lifesciences Invests Heavily in Capabilities in India and U.S.

The strategic investments by the CRDMO, which are aligned with its long-term strategy, will strengthen its integrated oligonucleotide platform and capabilities to delivery ADC solutions.

Bionova to Open pDNA Development and Production Facility in Texas
Bionova to Open pDNA Development and Production Facility in Texas

The location of the facility has been purposefully chosen to be as central as possible to cell and gene therapy companies located across the U.S. and will allow the company to meet growing demand for pDNA development and manufacturing services.

Strategy

Featured
Novo Unveils Transformation Plans to Better Compete in the Obesity Market
Novo Unveils Transformation Plans to Better Compete in the Obesity Market

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

The Road Ahead for Resilient Supply Chains
The Road Ahead for Resilient Supply Chains

Industry leaders delve into the latest biopharma supply chain disruptions and provide insights into approaches that can help to reduce vulnerabilities and ensure greater resilience in the future.

Balancing Innovation with Integrity in Pharma Packaging
Balancing Innovation with Integrity in Pharma Packaging

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

Cohance Appoints Yann D’Herve as New CEO
Cohance Appoints Yann D’Herve as New CEO

D’Herve has succeeded Dr. Singh, bringing a wealth of industry experience to the position, having previously served in senior positions at Evonik.

Regulatory

Featured
Intercept Withdraws Liver Disease Drug from U.S. Market
Intercept Withdraws Liver Disease Drug from U.S. Market

The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

Viatris’ Generic Iron Sucrose Gains FDA Nod
Viatris’ Generic Iron Sucrose Gains FDA Nod

FDA has granted approval to Viatris for its generic intravenous iron replacement product as a treatment of iron deficiency anemia in adult and pediatric patients with chronic kidney disease.

FDA Accepts GSK’s Gepotidacin for Priority Review
FDA Accepts GSK’s Gepotidacin for Priority Review

If the oral antibiotic gains regulatory approval, patients who are 12 years of age and older in the U.S. suffering from urogenital gonorrhea will have an alternative, non-invasive treatment option.

Sean Keveney Named FDA’s Next Chief Counsel
Sean Keveney Named FDA’s Next Chief Counsel

This latest FDA leadership appointment comes as the agency focuses on balancing regulatory challenges with opportunities for accelerated patient access.

Upcoming Events

Featured
7th RAS-Targeted Drug Development Summit

Returning for its 7th year, the RAS-Targeted Drug Development Summit remains the only industry-focused meeting dedicated to targeting all RAS mutations in the fight against a wide array of cancers.

DPHARM 2025

The 15th Annual DPHARM® offers an unparalleled opportunity to hear senior clinical operations executives and innovative thought leaders unveil the latest innovations on modernizing clinical trials.

ILMAC 2025

Ilmac is where the life sciences industry meets, moves, and makes deals. Ilmac has its origins in the Swiss trade fair for laboratory, measurement technology and automation in the chemical industry, which was held for the first time in Basel in 1959.